You have 9 free searches left this month | for more free features.

Lenvatinib

Showing 1 - 25 of 454

STUDY
CONDITIONS
INTERVENTIONS
LOCATIONS

Liver Cancer, Hepatocellular Carcinoma, Resistant Cancer Trial in Shanghai (Lenvatinib Oral Product Plus VIC1911)

Not yet recruiting
  • Liver Cancer
  • +2 more
  • Lenvatinib Oral Product Plus VIC1911
  • Shanghai, China
    Deparment of Liver Surgery, Ren Ji Hospital, School of Medicine,
Jan 30, 2023

Liver Diseases, Hepatocellular Carcinoma, Immunotherapy Trial in Guangzhou (bTAE-HAIC, Lenvatinib, Sintilimab)

Not yet recruiting
  • Liver Diseases
  • +4 more
  • bTAE-HAIC
  • +2 more
  • Guangzhou, Guangdong, China
    Sun Yat-sen University Cancer Center
Sep 30, 2023

GBM Trial (Lenvatinib, Pembrolizumab, Tumor Treating Fields (TTFields))

Not yet recruiting
  • GBM
  • Lenvatinib
  • +2 more
  • (no location specified)
Aug 2, 2023

Hepatocellular Carcinoma Trial in Seoul (Lenvatinib)

Recruiting
  • Hepatocellular Carcinoma
  • Lenvatinib
  • Seoul, Korea, Republic of
    Asan Medical Center
Nov 14, 2023

Hepatocellular Carcinoma Trial in Guangzhou (Lenvatinib, Tislelizumab Combined with RALOX Regimen HAIC)

Recruiting
  • Hepatocellular Carcinoma
  • Lenvatinib, Tislelizumab Combined with RALOX Regimen HAIC
  • Guangzhou, Guangdong, China
    Guangdong Provincial People's Hospital
Jul 12, 2023

Solid Tumor, Adult Trial in Shanghai (Tislelizumab, Lenvatinib, Cryoablation)

Recruiting
  • Solid Tumor, Adult
  • Shanghai, Shanghai, China
    Fudan University Shanghai Cancer Center
Sep 13, 2023

Hepatocellular Carcinoma Non-resectable Trial in Guangzhou (Lenvatinib plus sintilimab, Lenvatinib)

Recruiting
  • Hepatocellular Carcinoma Non-resectable
  • Lenvatinib plus sintilimab
  • Lenvatinib
  • Guangzhou, Guangdong, China
    The Second Affiliated Hospital of Guangzhou Medical University
Nov 2, 2022

Hepatocellular Carcinoma Trial in Guangzhou (Lenvatinib, sintilimab plus SIRT)

Not yet recruiting
  • Hepatocellular Carcinoma
  • Lenvatinib, sintilimab plus SIRT
  • Guangzhou, Guangdong, China
    The Second Affiliated Hospital of Guangzhou Medical University
Aug 8, 2023

Hepatocellular Carcinoma Non-resectable Trial in Guangzhou (Lenvatinib Plus I-125 Seed Brachytherapy, Lenvatinib)

Recruiting
  • Hepatocellular Carcinoma Non-resectable
  • Lenvatinib Plus I-125 Seed Brachytherapy
  • Lenvatinib
  • Guangzhou, Guangdong, China
    The Second Affiliated Hospital of Guangzhou Medical University
Nov 2, 2022

Hepatocellular Carcinoma Trial in Beijing (Lenvatinib Plus Tislelizumab, Transarterial Chemoembolization(TACE))

Recruiting
  • Hepatocellular Carcinoma
  • Lenvatinib Plus Tislelizumab
  • Transarterial Chemoembolization(TACE)
  • Beijing, Beijing, China
    Nan Zhang
Apr 22, 2023

Potentially Resectable Hepatocellular Carcinoma Trial (FOLFOX-HAIC+Lenvatinib+Envolizumab)

Not yet recruiting
  • Potentially Resectable Hepatocellular Carcinoma
  • (no location specified)
Nov 16, 2023

Hepatocellular Carcinoma Trial (Cryoablation, Tislelizumab, Lenvatinib)

Not yet recruiting
  • Hepatocellular Carcinoma
  • Cryoablation
  • +2 more
  • (no location specified)
May 31, 2023

Liver Diseases, Hepatocellular Carcinoma, Immunotherapy Trial in Guanzhou (bTAE-HAIC, Lenvatinib, Camrelizumab)

Not yet recruiting
  • Liver Diseases
  • +4 more
  • bTAE-HAIC
  • +2 more
  • Guanzhou, Guangdong, China
    Sun Yat-sen University Cancer Center
Sep 24, 2023

Endometrial Cancer, Endometrial Adenocarcinoma Trial in Guangzhou (Cadonilimab, Lenvatinib)

Not yet recruiting
  • Endometrial Cancer
  • Endometrial Adenocarcinoma
  • Guangzhou, China
    Sun Yat-sen University Cancer Cetntre
Apr 9, 2023

PD-1 Refractory Advanced Melanoma Trial in Pittsburgh (Responder-Derived Fecal microbiota transplantation (R-FMT, Pembrolizumab,

Not yet recruiting
  • PD-1 Refractory Advanced Melanoma
  • Responder-Derived Fecal microbiota transplantation (R-FMT
  • +2 more
  • Pittsburgh, Pennsylvania
    UPMC Hillman Cancer Center
Sep 1, 2023

Advanced Biliary Tract Cancer Trial (H101, Tislelizumab, Lenvatinib)

Not yet recruiting
  • Advanced Biliary Tract Cancer
  • (no location specified)
Apr 11, 2023

Hepatocellular Carcinoma Trial (TACE(transcatheter arterial chemoembolization), lenvatinib, Icaritin soft capsules)

Not yet recruiting
  • Hepatocellular Carcinoma
  • TACE(transcatheter arterial chemoembolization)
  • +2 more
  • (no location specified)
Jun 5, 2023

Unresectable Hepatocellular Carcinoma Trial in Nanchang (D-TACE, HAIC, Lenvatinib)

Recruiting
  • Unresectable Hepatocellular Carcinoma
  • Nanchang, Jiangxi, China
    The Second Affiliated Hospital of Nanchang University
Oct 14, 2022

Resectable Hepatocellular Carcinoma Trial (Tislelizumab, Tislelizumab, Lenvatinib)

Not yet recruiting
  • Resectable Hepatocellular Carcinoma
  • (no location specified)
Mar 29, 2023

Advanced Hepatocellular Carcinoma Trial in Chengdu (Lenvatinib combined with TACE and Camrelizumab)

Recruiting
  • Advanced Hepatocellular Carcinoma
  • Lenvatinib combined with TACE and Camrelizumab
  • Chengdu, Sichuan, China
    HuaXi hospital
Feb 12, 2023

Breast Tumors Trial in Hangzhou (Sindilimab, Nab-paclitaxel, Lenvatinib)

Not yet recruiting
  • Breast Neoplasms
  • Hangzhou, Zhejiang, China
    ZhejiangCH
Nov 17, 2023

Gastric Cancer Metastatic to Liver Trial in Shanghai (Cryoablation, Tislelizumab, Lenvatinib)

Not yet recruiting
  • Gastric Cancer Metastatic to Liver
  • Cryoablation
  • +2 more
  • Shanghai, Shanghai, China
    Fudan University Shanghai Cancer Center
Jun 6, 2023

Cadonilimab, Clear Cell Renal Cell Carcinoma, Neoadjuvant Therapy Trial in Guangzhou (Cadonilimab Combined With Lenvatinib)

Recruiting
  • Cadonilimab
  • +2 more
  • Cadonilimab Combined With Lenvatinib
  • Guangzhou, Other (Non U.s.), China
    Sun Yat-sen University Cancer Center
Nov 16, 2023

Head and Neck Squamous Cell Carcinoma, Cutaneous Squamous Cell Carcinoma, Head Neck Cancer Trial in United States (Lenvatinib

Completed
  • Head and Neck Squamous Cell Carcinoma
  • +3 more
  • Basking Ridge, New Jersey
  • +6 more
Oct 13, 2022

Hepatocellular Carcinoma Trial in Wuhan (Sintilimab, Lenvatinib, Transarterial Chemoembolization (TACE))

Not yet recruiting
  • Hepatocellular Carcinoma
  • Wuhan, Hubei, China
    Tongji Hospital, Tongji Medical College, Huazhong University of
Oct 17, 2023